Drugs in the Pipeline
Psilocybin Study Gets Green Light From FDA for Treatment-Resistant Depression
The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.
Your search for psilocybin returned 16 results
Drugs in the Pipeline
Psilocybin Designated Breakthrough Tx for Major Depressive Disorder
The FDA has granted Breakthrough Therapy designation to psilocybin for the treatment of major depressive disorder.
News
Psychedelic May Help with Smoking Cessation, Says Study
According to a study in The American Journal of Drug and Alcohol Abuse, psilocybin showed promise in promoting long-term smoking abstinence in the context of a structured treatment program.
News
Psilocybin + Psychotherapy Cuts Heavy Drinking Days in Alcoholism
Percentage of heavy drinking days reduced with psilocybin combined with psychotherapy versus active placebo plus psychotherapy
News
Psilocybin Compared With Escitalopram for Depression
No difference seen in change in depression scores at six weeks for psilocybin plus placebo versus psilocybin plus escitalopram
News
Hallucinogenic Drug Reduces Anxiety, Depression in Distressed Cancer Patients
A single moderate-dose of psilocybin (a hallucinogenic compound contained in psychedelic mushrooms) was found to produce enduring anxiolytic and antidepressant effects in distressed cancer patients with life-threatening diagnoses.
News, Psychiatric Disorders
Benefits of Psilocybin-Assisted Psychotherapy May Be Lasting
Reductions in anxiety, depression in cancer-related psychiatric distress sustained at 3.2 and 4.5 years.
News
Magic Mushroom Compound Investigated in Treatment-Resistant Depression
Results from a recent study published in The Lancet Psychiatry demonstrates preliminary support for the safety and efficacy of the hallucinogenic compound, psilocybin, for the management of treatment-resistant depression.
Drug News
Magic Mushroom Rx May Lift Mood in Those Battling Life-Threatening Diseases
A single dose of psilocybin can alleviate negative moods in patients with life-threatening cancer, a new study has found.
News
Researchers Recommend Reclassification of Psilocybin
Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I agent as it has not been approved by the Food and Drug Administration (FDA) for any therapeutic use.
